EagleClaw Capital Managment LLC Has $2.54 Million Stock Position in Sanofi $SNY

EagleClaw Capital Managment LLC boosted its holdings in shares of Sanofi (NASDAQ:SNY) by 14.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 52,585 shares of the company’s stock after acquiring an additional 6,760 shares during the quarter. EagleClaw Capital Managment LLC’s holdings in Sanofi were worth $2,540,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in SNY. Ameritas Advisory Services LLC acquired a new stake in shares of Sanofi during the second quarter worth approximately $28,000. Accent Capital Management LLC acquired a new stake in shares of Sanofi during the 1st quarter valued at $29,000. Eastern Bank grew its holdings in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock valued at $30,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA acquired a new position in shares of Sanofi in the first quarter worth $33,000. Finally, Brentview Investment Management LLC purchased a new stake in shares of Sanofi during the first quarter worth $42,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Stock Up 0.4%

Shares of Sanofi stock opened at $51.92 on Thursday. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. The stock has a 50 day moving average price of $48.75 and a two-hundred day moving average price of $49.45. The stock has a market capitalization of $127.49 billion, a P/E ratio of 12.16, a PEG ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. The company had revenue of $14.53 billion for the quarter, compared to analyst estimates of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The company’s quarterly revenue was down 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $2.25 earnings per share. Equities analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on SNY. Wall Street Zen upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Jefferies Financial Group restated a “buy” rating on shares of Sanofi in a report on Monday, October 27th. Weiss Ratings reiterated a “hold (c)” rating on shares of Sanofi in a research note on Tuesday. Finally, Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.